MYL9

myosin light chain 9, the group of Myosin light chains, class 2

Basic information

Region (hg38): 20:36541497-36551447

Links

ENSG00000101335NCBI:10398OMIM:609905HGNC:15754Uniprot:P24844AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • megacystis-microcolon-intestinal hypoperistalsis syndrome 4 (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Megacystis-microcolon-intestinal hypoperistalsis syndrome 4ARGastrointestinal; RenalIndividuals have been described as benefiting from surgical interventions, including related to renal anomalies and nephrolithiasis; Multivisceral transplantation has been describedGastrointestinal; Genitourinary; Musculoskeletal; Ophthalmologic; Renal27481187; 29453416; 33031641

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the MYL9 gene.

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the MYL9 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
0
missense
10
clinvar
10
nonsense
0
start loss
0
frameshift
0
inframe indel
0
splice donor/acceptor (+/-2bp)
1
clinvar
1
splice region
0
non coding
0
Total 0 0 11 0 0

Variants in MYL9

This is a list of pathogenic ClinVar variants found in the MYL9 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
20-36545018-G-A not specified Uncertain significance (Jan 26, 2023)2479893
20-36545063-CGCTGGGTGA-C Visceral myopathy 1 • Megacystis-microcolon-intestinal hypoperistalsis syndrome 4 Uncertain significance (Feb 26, 2020)818204
20-36548060-G-C not specified Uncertain significance (Dec 08, 2023)3159626
20-36548137-C-T not specified Uncertain significance (Feb 27, 2023)2456943
20-36548145-G-A not specified Uncertain significance (Jan 26, 2022)2379836
20-36548163-G-A not specified Uncertain significance (Aug 13, 2021)2351120
20-36548173-G-C not specified Uncertain significance (Nov 18, 2022)2328036
20-36548178-G-A not specified Uncertain significance (Apr 15, 2024)3297582
20-36548743-GTGGAACTCCAGAGCTCACGCTTAAAACAGGGCACACCCAACACCATCTGTGTGCACAGCCTCAAGTTCCCCAAGTGACACCTCGGAGACAGTCCCACTGCACAACTCCTCCCCTCAGGACCCTGGCACCCCTTCACGTGGGATCCGACACCCCTTCACGTGCACCCCCACACCCCTCCTGCCACGTCCTCATTCCTCAGACTGACCAGAGACTAAGATTGTATCTTCCCAGCCCCTCTAGGTCTGCAAGAGCTGCCAGGGGGCTGAGGGATGGGGCTGCTGTGTATGTCTCAGCCCAAGTTCCTGCTCTCACCCACCCTGCCCCTGCCCGCAGGTTTCATCCATGAGGACCACCTCCGGGAGCTGCTCACCACCATGGGTGACCGCTTCACAGATGAGGAAGTGGACGAGATGTACCGGGAGGCACCCATTGATAAGAAAGGCAACTTCAACTACGTGGAGTTCACCCGCATCCTCAAACATGGCGCCAAGGATAAAGACGACTAGGCCACCCCAGCCCCCTGACACCCCAGCCCCCGCCAGTCACCCCTCCCCGCACACACCCGTCCATACCAGCTCCCTGCCCATGACCCTCGCTCAGGGATCCCCCTTTGAGGGGTTAGGGTCCCAGTTCCCAGTGGAAGAAACAGGCCAGGAGAAGTGCGTGCCGAGCTGAGGCAGATGTTCCCACAGTGACCCCAGAGCCCTGGGCTATAGTCTCTGACCCCTCCAAGGAAAGACCACCTTCTGGGGACATGGGCTGGAGGGCAGGACCTAGAGGCACCAAGGGAAGGCCCCATTCCGGGGCTGTTCCCCGAGGAGGAAGGGAAGGGGCTCTGTGTGCCCCCCAGGAGGAAGAGGCCCTGAGTCCTGGGATCAGACACCCCTTCACGTGTATCCCCACACAAATGCAAGCTCACCAAGGTCCCCTCTCAGTCCCCTTCCCTACACCCTGACCGGCCACTGCCGCACACCCACCCAGAGCACGCCACCCGCCATGGGAGTGTGCTCAGGAGTCGCGGGCAGCGTGGACATCTGTCCCAGAGGGGGCAGAATCTCCAATAGAGGACTGAGCACTGCTTCTGGTCTGTGTGTCTGTGGCTGGGGTGAAGTAAGGGGACCCCGGGCCTGAAACCCTCTCCCACCTTCTCCTGCCATCTCCAGTTACTGCCCTGCTCCTCCCACCCTGGCCCAGGGAAGGACTGGGTGTCCTCCGGCCATATGGTCCCTGAAGCCTCTAGGGACCAGAGTCCCTAGTAAGTGGGCTCTGTGCTCAGCTGAGACCAGCAGGGGACAGGGGACGGAGGGAATGGGCCTCATGGCCTTCTCAGGGCTTGTGGGAAAGGGAGGACCATGGGAATCACCACAGCCAATCCCGTGGAGGGTTCCAGGCCTCTTGGGGGGCAGAGGTCAGGCCACACAGCCCTCAGGACTAAAGCTCCGGGTTCCAGAAGAACAGGGAGGCTCCAACAGTGATGAGGCAGGCGTCCCAGCAGCTCAGGGTTGGAGGTGGGAATGAGGGGTTTCCCAGCCCCAGGCAGGTGGAGGGCGAGTTCAGCCCCAGGACCAACAGCATGGGGGCCACAGCTTTCCATGTCCCTGTGTACGCAGGGCAGGCAGGGCCGGGACCCCTGCTACTGGTGGATGATGGGGACACTGATGGCAGTGCCTGGGGCCTAAGAGGGGCAGAAAGAGCGCTGAATGACTGAGCAGAGAGTCCAGAGGGGCATGGACTGCCTGGGTCACCCAATAGGCCTAGGGAAGAGTGAGGGCCGGACCCACCCCACCTGACCCCAGCGAGTGGACCCAGCTTGGTCCTGAGGCCTTCTCCAGAGGTCACCCAGCGCAGGCAGCCGCAGCACTCAGCAAAGGTCCCAGATCAGGGCCAAGGGGGAGCTGAGCACCAGGGGACCCTGTGCCTGACCAGGAGGCCCTAACCTCCTGCAGGCCTCAACGCCAGGCCCTGCTCAGAGCTCGGCTGAAACTCCTCATCCTGGCTCCAAACAGAGGCCCAAAAGTCCCTGGTATCAACTCCAGAAGGGGCGAGACCCGAACAAGTTCCAAACCAGGCCCAAATAGTATCCCAAACTCAGTCCCAAACACATTCTCACCCCCGGCAGCAGGCTGCAGGCCTCCAGCTACACACACGGCCCTGGGCAACTCTCAGTCTGGCCACCCATTCGATGCTGCCAGCCCCAAGGGTGTGGGAGGGGGGTCTCAGAGTGTCCCAGGGTACTGGCCACACATGCCCGACACCAGGGTCATAAGGTCCTCTCAGCAGAGCCACTGCAGCACCAAAGGCATTTCTGGAAGGAGGCAAGGACGCGTCATCTAGATGTCAAGCCCCAGCGTGCGATTCTGTCACAGTTCACCCCACCTTCACCCCGAGACGGAAGACGGAAGAGCTTCGCACACAGGCGGGAAGAGGTCAGGACCAGTCCAGCCTCACTGGCTTCAGAACTGGCCTGGGGGCTACCTTGACCCACAGGAAGGGAAGAGGAACGTGCTCTGGGCAGGGCAAGGCAGGACCTGCAGCACCCACAGACCAGCAGTAAAGGACCCCCGGAACTTTCCAAGTCTAGCACAAAACCCAGAAGCCACAAAGGAAAATACTGGCAGATTTAAATGCATGAAGTCAACATTCTTTTTGTAGAGCTAAAGAAACCATAAGCAAAATTAAAAGCCAAATGCATTCTGGGAGGAAATACCTGCAGCATATTTAACAAAACAAGAGTTAACACTAATCTATATAAAGCTTCAGTAATTGAATCAGAAAAAGACAACGCCGTAGGAAAAAAATGGTAACATGAAAAGGAATCTCAGAAGAAATGCATATACTTATTTTTTTCTTTTTTTTTTGAGACAGAGTCTCGCTCTTTCTCCCAGGCTGGAGTGCAGTGGCGTGATCTCGGCTCACTGCAACCTCCGCCTCCCGGGTTCAAGTGATTCTCCTGCCTCAACCTCCCAAGTAGCTGGGACTACAGGTGTGCGCCACCACGCCCAGCTAATTTTTGTATATTTAGTAGAGACAGGGTTTCACCATGTTCGCCAGATGGTCTCCATCTCTTGACCTTGTGATCCACCCACCTTAGCCTCCCAAAGTGCTGGGATTACAGGGGTGGGCCACCACGCCCGGCCAAAATACATACACTTAATAAGAACATTTTAAATACTCACCAAATACATTTTTAAGTGCTCAACATCATTGTAAAACTGTAAAATTTTCTATTTTTTCCTAGTATTTGTCTAGCTTTTTCAGACTGGGTCTTTCTGTTGCTCAGGCTGGAGTGCAGTGGTGTGATCATAGGTCCCTGCAGCCTAGAACTCCTGGGCTCAAGCAATTCTCCCACCTCAGCCTCCTGAGCAGCTGCTACTACAGACCTGTGCCACCACGCCTGACTAATTTTTTATTTTTTGTAGAGAGAGGATCTTGCTATGTTGCCCAGGCTGGTGTCAAACTCCTGGGCTCAAGCAATCCTCCCACCTTGGCCTCTCAAAGTGGTGAGATTACAAGTGTGAACCACCACACCTGGCCTTAATTTTTTAATTTTTGTGGTTTTTCTCTTTTGAGACAGAGTTTCACTCTTGTTGCCCATGCTGGAGTGCAATGGCACGATCTCAGCTCACGGCAACCTCCCAGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGATCACAGGCAGCCGCCACCACGCCTGGATAACTTTTTGTATTTTTAGTAGAGAGGGGGTTTCACTATGTTGGCCAGGCTGGTCTCGAACTCCTGACATCAGGTGATCCACCTGCCTTGGCCTCCCAAAGTGCTAGGATTACAGGCATGTGCCACTGCACCTAGCCAATTTTTAAATTTTTGGTAGAGATGGGGTCTCGCTTTGTTGCCTGGGCTGGCCTCAAACTCTTGGCCTCAAGTGATCCTTCTGCCTCAGCCTCCCAAGTAGCTAAGACTACAAACACATACCACCACACCTGACAGAGTCCTTTTTTTAAATTCCTCCAAAGGCTAGCACTTTTAAAACATTAGAAATTCCATTTATTTTCTGAAAATTTTTGTGTTTCCTTATCTTTCTGGCAGCCTCATTAGACCTTATAATAGAATCAAAATGAATCTTAAACTTTTTTTTTTGAGACTCAGTTTCACTCTGTCACCCAGAATGGAGTACAGTGGTGTGATCTCAGTTCACTGCAACCTCCGCCTCCCAAGTTCAAGTGATTCTCCTGCCTCAGCTCCCCAAGTAGCTGGGATTACAGGCACGCACCACCATGTTCAGCTAATTTTGTATTTTTAGTAGAGCTGGGGTTTCACCATGTTGGTCAGGCTGGCCTTGAACTCCTGACCTCAGGTGATCTACCCACCTCTGCCTCCCAAAGTGCTTGGGATTACAGGCGTGAGCCACAGCAACCGGCCTAGATCTTAAAATTTAAGAGACATTATAATTTAATTTGATATACTATGGTGGTAGAAAAACATTTCAAACTCATATAGATACAGAAACTTGGAAGCTTCAGTTCTACAGTCTTTCATACATCAAGTTAAACCAAAAAACACAAAAACTCACTGATCCACATCTCAATGGGCTTTCTCCTTTCAGTGTTTCCTTAAGTGACTTGAGATCACAAACATGCAAAATAACGACCAAAAAAACCTAACAAATCAGGTTTCCTGTCATCTCTCTCTAGATAAAAAACAGACCCCCACCGTCCTGATGGAGATAAACTAAGAGATCATAAAATCATTGTTGCCAGCTATGAGAAACAGCTTGGTCAAGAGCCAGAAACAAAACAGAGAATCAGGCCAGCCTCAGTGGCCCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCAGGCAGATCACACGAGGTCAGGAGTTCGAGGCTAGCCTGGCCAACATGGTGAAACCTCATCTCCACTAAACATACAAAAATTAGCCAGGTGTGGTGGGGCACACCTGTAGTCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATCACTTGAACCCGGGAGGTGGAGACTACAGTGAGCTGAGATCGTGCCACTGCACTCCAGCCTGGGCAACAGAGTGAGATGCCGTCTCAAAAAAAGAAAAGAGGCTGGGGCGGGAGGATCGCTGGAAACCAGAAGTTCAAGGCTACACTGAGCTATGATTGCACCACTGCACACCAGCCTGGGTGACAGAGGGAGACTCTGTCTCTAAAAGTATATAAATAAATAAATAAACAAAAAAGGAAAGATAGACAGATGGGGGAAAACACCAGAGTCCGTGAAAGTATTTTGTTGTTGTTGTTGTTGTTGTTCTTTTTTGAGACAAAGTCTCGCTCTGTCACCCAGGCTGGAGTGCAGTGGTGCGATCTCGGCTCACTGCAATGTCCACCTCCTGGGTTCAAACGATTCTCCTGCCTCAGCCTCCAGACTAGCTGGGATTATAGGCACACACCACCACACCCACCTAACTTTTATATTTTTAGTAGAGACTGGGTTTCACCATGTTGGCCAGGCTGGTCTCGAACTTCTGACCTCAGGTGATCTACCCACCTCGTCCTCCCAAAGTGCTGAGATTACAGGTGTGAGCCACCACACCTGGCCTTACTGTATTGTTTTTTGGTGGTATTGTTATTTTTATTGGTTTTTTCTTTTTTTGTGATGGAGTTTCGCTCTTGCTGCCCAGGCAGGAGTGCAATGGCGAAATCTCGGCTCACTACAACCTCCGCCTCCTGGGTTTAAGCGATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACAGGCATGCACCACCATGCCTGGCTAATTTTGTATTTTAAGTAGAGACGGGGTTTTACCATGTTGATCAGACTGGTCTCAAACTCCCAACCTCAGGTGATCTGCCTGCCTCGGTCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACTGCGCCGCTCATTTTTTTTTTTTTCTGTAGAGGCAGTCTCCCTATGTTGCCCAGACTAGTCTCAAATTCCTGGGCTCAAGTGATCCTCCTGCCTCATGATATTTTCTATCTGAAGTTGGTTGAATCCATGGATGCAGAACCTGCAGATATGAAGGGACAACTGCAGTCAGAAAGAAAAGCAAATTAAAAATAAGAAGCCACTTTATGCCCATCAGATTGTCAAAATTTGGAGAGAGGGATGATACCATTGGAAAAGATGCAGAGAATCCTAAGGCGATGAGAGGACAGACTGGCGCACCAGTGCAGGACAGCAACCACGCAGCACCTGTGAGCAAGCAAATCCCTTCTGATGCAGCAACTCCACACTTGGAAACGTATACCAGAGGAATTGTGCATAGGCCCAGAAGGGGCAGGAACAGTTCACTGAGGCAGCACTGACAGTAACAGGGAACTGGAGGGGACCTACTTATCTATCAAGAGGAAAATCAGTAAGTGAAACGTGATGAATGCATACTGTGGATACCATGCAGGACTCAATGTCCATACCTCAACAGGGCTGCATATCAAAAGCAATATGAGGGAGAAAAGACATGGGATGAGAGTATCGCCCAAGAACTTCAGTGTAATTTTAAAACATGCAGACTTAACCACTGCAGAATTGCCCAGGGGACTCTTCATACATAGCCAAGGACCCATTCAAAACCCTCAAGAGTGGATTCCTAGGGTGAGGTGGGGCTTAGAGGTAGTGCCTGGGGACATATTGATGGCCTTGTGTCCTGAATGCAGTGTGTCATATGCAAGTGAGGAGGACAAGGAAGAGATGGGGCCACGCTGACTGGGAAGAGAGAAAGAGTGAAGCTTATATAAGATAGTACCTGAAATTAACAGGGTCCTACCTGATGAATAAACCTCAATAAGGACAAGCATGGATGGAGAAAGGACACAAGAACTGATTGAGGTCTATCTGGAATTCAGGAGGAACCCTGGTCATTACCTTTAACTGATGAAAAAACAAAGCCAATCGCCCAGGCGCAGGGGCTCATGCCTGTA-G Visceral myopathy 1 Likely pathogenic (Aug 31, 2017)437907
20-36549127-C-T not specified Uncertain significance (May 29, 2024)3297581
20-36549156-G-A not specified Uncertain significance (May 24, 2024)3297579
20-36549161-G-A not specified Uncertain significance (Dec 28, 2022)2213404
20-36549175-G-C Uncertain significance (Aug 08, 2021)1677428
20-36549240-A-C not specified Uncertain significance (Aug 04, 2021)2241405
20-36549241-G-C not specified Uncertain significance (Aug 04, 2021)2230425

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
MYL9protein_codingprotein_codingENST00000279022 38342
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.01980.7571257280181257460.0000716
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.17831190.6980.000007731176
Missense in Polyphen1730.8660.55077364
Synonymous0.3754346.20.9300.00000332301
Loss of Function0.84135.040.5962.13e-763

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0001460.000146
Ashkenazi Jewish0.000.00
East Asian0.0002770.000272
Finnish0.000.00
European (Non-Finnish)0.00007110.0000703
Middle Eastern0.0002770.000272
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Myosin regulatory subunit that plays an important role in regulation of both smooth muscle and nonmuscle cell contractile activity via its phosphorylation. Implicated in cytokinesis, receptor capping, and cell locomotion. {ECO:0000269|PubMed:11942626, ECO:0000269|PubMed:2526655}.;
Pathway
Focal adhesion - Homo sapiens (human);Oxytocin signaling pathway - Homo sapiens (human);Tight junction - Homo sapiens (human);Regulation of actin cytoskeleton - Homo sapiens (human);cAMP signaling pathway - Homo sapiens (human);Vascular smooth muscle contraction - Homo sapiens (human);cGMP-PKG signaling pathway - Homo sapiens (human);Leukocyte transendothelial migration - Homo sapiens (human);Focal Adhesion;Striated Muscle Contraction;RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function;Developmental Biology;Smooth Muscle Contraction;Signal Transduction;Gene expression (Transcription);Generic Transcription Pathway;RNA Polymerase II Transcription;RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function;EPH-Ephrin signaling;EPHA-mediated growth cone collapse;RHO GTPases Activate ROCKs;RHO GTPases activate PAKs;RHO GTPases activate PKNs;RHO GTPases activate CIT;Muscle contraction;RHO GTPase Effectors;Signaling by Rho GTPases;Sema4D induced cell migration and growth-cone collapse;Sema4D in semaphorin signaling;Semaphorin interactions;Axon guidance;Integrin-linked kinase signaling;Transcriptional regulation by RUNX1 (Consensus)

Recessive Scores

pRec
0.149

Intolerance Scores

loftool
0.626
rvis_EVS
-0.16
rvis_percentile_EVS
41.25

Haploinsufficiency Scores

pHI
0.284
hipred
N
hipred_score
0.455
ghis
0.646

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.982

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Myl9
Phenotype

Gene ontology

Biological process
muscle contraction;regulation of muscle contraction;regulation of megakaryocyte differentiation;platelet aggregation
Cellular component
stress fiber;cytosol;muscle myosin complex;Z disc
Molecular function
calcium ion binding;structural constituent of muscle;myosin heavy chain binding